Search Site

Andrew B. Lassman, MD

  • John Harris Associate Professor of Neurology
  • Chief, Division of Neuro-Oncology
  • Co-Director, Brain Tumor Center
Andrew B. Lassman, MD

Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University. After earning BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, he received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.

In November 2011, Dr. Lassman became Chief of Neuro-Oncology at Columbia University Medical Center, and also serves as the Medical Director for the Clinical Protocol Data Management Office of the Herbert Irving Comprehensive Cancer Center.

Dr. Lassman received the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. His clinical practice is limited to central nervous system tumors and metastases.

Dr. Lassman's research interests focus on translational clinical trials for brain tumors with molecular correlative analyses to understand the reasons for treatment success or failure, and to refine treatment paradigms.

Departmental Appointments

  • Department of Neurology
    Division of Neuro-oncology

Board Certifications

  • Neurology

Areas of Expertise

  • Neuro-Oncology
  • Cancer Care
  • Brain & Spinal Tumors
  • Acoustic Neuroma
  • Astrocytoma
  • Anaplastic Astrocytoma
  • Brain Tumor
  • Brain Metastases
  • Brain Stem Glioma
  • Brain Cancer
  • Carcinomatous meningitis
  • Chordoma
  • Choroid Plexus Papilloma
  • Choroid Plexus Carcinoma
  • Ependymoma
  • Gliomas
  • Glioblastoma
  • Glioblastoma Multiforme
  • Hemangioblastoma
  • Leptomeningeal metastases
  • Medulloblastoma
  • Meningioma
  • Metastatic Cancer
  • Mixed Glioma
  • Neurofibromatosis
  • Oligodendroglioma
  • Oligoastrocytoma
  • Second Opinion
  • Spinal Cord Tumor
  • Spinal Tumors

Education & Training

  • MD, Columbia University College of Physicians and Surgeons
  • Internship: Mount Sinai Hospital
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Locations

  • Neurological Institute of New York

    710 West 168th Street
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 342-0571
    Fax:
    (212) 342-1246

Centers/Institutes/Programs

  • Herbert Irving Comprehensive Cancer Center

Provider Affiliations

  • NewYork-Presbyterian/Columbia

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]
  • Amida Care [Special Needs Plan]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Emblem/GHI [HMO, Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Multiplan [Multiplan]
  • Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
  • POMCO [POMCO]
  • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [Medicare Managed Care, SelectHealth]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider accepts new patients

Appointment Phone Number: (212) 342-0571

Contact Info

  • Office Phone: 212-342-0571
  • Fax: 212-342-1246

Presentations

Selected Invited Presentations

  • Grand Rounds, Columbia University, College of Physicians & Surgeons, Neurosurgery, July, 2001
    Wireless Worries: Do Cell-phones Cause Brain Tumors?
  • Faculty, 4th Annual Future of Supportive Therapy in Oncology, Dallas, February, 2006
    Central Nervous System Metastases
  • Faculty, Society for Neuro-Oncology Annual Meeting, November, 2007
    The Issue of Tissue: Clinical Trial Design for Targeted Therapies in Glioma
  • Faculty, 2nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2008
    Update on Treatment of Recurrent Glioblastoma
  • Grand Rounds, Barrow Neurological Institute, Neurology, October, 2008
    Glioblastoma
  • Faculty, Education Day, Society for Neuro-Oncology, Annual National Meeting, November, 2008
    Chemotherapy for Newly Diagnosed Anaplastic Oligodendroglioma?
  • Faculty, Education Session, ASCO, Annual National Meeting, May, 2009
    Management of Newly Diagnosed Anaplastic Oligodendroglioma
  • Faculty, 3nd Annual Symposium on Gliomas & Secondary Brain Tumors, November, 2009
    Current Approaches to Anaplastic Oligodendroglioma
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, Sept., 2009
    Glioblastoma
  • Platform Presentation, Joint Meeting of the Society for Neuro-Oncology and the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors, 2009
    International Retrospective Study of 1000+ Adults with Anaplastic Oligodendroglial Tumors
  • Grand Rounds, North Shore-LIJ Health System, Neurology, March, 2010
    Glioblastoma
  • Grand Rounds, NYU-Post Graduate Medical School, Neurology, June, 2010
    Newly Diagnosed Glioblastoma
  • Platform Presentation, Society for Neuro-Oncology, Annual Meeting, November, 2011
    Recursive Partitioning Analysis of Prognostic Variables in Newly Diagnosed Anaplastic Oligodendroglial Tumors
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Neurology, January 2012
    Glioblastoma: Past, Present, and Future
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Hematology Oncology, January 2012
    Brain Metastases
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, March 2012
    Oligodendrogliomas
  • Neuro-Oncology Symposium, John Theurer Cancer Center at Hackensack University Medical Center, April 2012
    Glioblastoma
  • Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2012
    Brain Tumor Biotech Summit
  • Discussant, Publications Scientific Session, Radiation Therapy Oncology Group, Semi-annual meeting, June 2012
    Molecular Markers in High Grade Gliomas: Effects on Practice?
  • Invited Speaker, Society for Neuro-Oncology, Annual National Meeting, November, 2012
    Anaplastic Glioma: New Challenges in the Era of Molecularly Based Treatment: PCV or Temozolomide?
  • Faculty, American College of Radiation Oncology Annual meeting, February 2013
    Anaplastic Oligodendrogliomas: Latest treatments and controversies
  • Grand Rounds, Weill Cornell Medical College , Neurosurgery, March 2013
    Glioblastoma: Past, Present, and Future
  • Invited Lecturer, Columbia University, Mailman School of Public Health, Neuroepidemiology, April 2013
    Brain Tumor Epidemiology
  • Seminar Speaker, Columbia University College of Physicians & Surgeons, Hematology-Oncology, April 2013
    Glioblastoma: Past, Present, and Future
  • Research Seminar Series, Columbia University College of Physicians & Surgeons, Pediatric Hematology/Oncology, April 2013
    Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Radiation-Oncology, May 2013
    Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
  • Grand Rounds, Columbia University College of Physicians & Surgeons, Neurosurgery, May 2013
    Anaplastic Oligodendrogliomas: Latest Treatments and Controversies
  • Faculty, Update in Neuro-Oncology, Omniprex International, March 2013
    Low Grade Gliomas and Anaplastic Gliomas
  • Faculty, American Society for Clinical Oncology, Annual National Meeting, June 2013
    Scientific Discussant, Clinical Science Symposium: The Importance of Molecular Markers in Anaplastic Gliomas
  • Faculty, Society for Neuro-Oncology, Annual National Meeting, November, 2013
    Controversies in Neuro-Oncology: PCV vs. Temozolomide for Anaplastic Oligodendrogliomas
  • Faculty, Weill Cornell Brain and Spine Center, Weill Cornell Cancer Center, June 2013
    Brain Tumor Biotech Summit

Teaching Responsibilities

Neurology resident didactic speaker on central nervous system tumors and metastases.  Teaching attending for outpatient and inpatients in Neurology Department.

Committees/Societies/Memberships

American Medical Association, Member

American Academy of Neurology, Member

Society for Neuro-Oncology, Member

American Society of Clinical Oncology, Member

Radiation Therapy Oncology Group, Brain Committee

Society for Neuro-Oncology, Annual Meeting, Abstract Review Committee

NIH Common Terminology Criteria for Adverse Events (CTCAE) Revision Committee

United Council for Neurologic Subspecialties Board, Neuro-Oncology Representative

Voices Against Brain Cancer Medical Advisory Board

American Society of Clinical Oncology, Scientific Program Committee, CNS Track

American College of Radiation Oncology, Scientific Program Committee

 

Honors & Awards

  • Neurology Resident Teaching Award, Memorial Sloan-Kettering Cancer Center/Weill Medical College of Cornell University
  • Preuss Award in Neuro-Oncology, American Academy of Neurology
  • Boyer Clinical Research Award, Memorial Sloan-Kettering Cancer Center
  • Gary Lichtenstein Humanitarian Award, Voices Against Brain Cancer

Research Interests

  • Translational clinical trials for brain tumors
  • Brain and leptomeningeal metastases

NIH Grants

  • A STUDY OF RADIOLOGICALLY EVIDENT TREATMENT EFFECTS IN SUBJECTS WITH GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)

    May 15 2017 - May 15 2022

    A PHASE 2, MULTICENTER STUDY OF TESEVATINIB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

    Apr 18 2017 - Apr 18 2022

    PHASE I/II DOSE ESCALATION TRIAL TO ASSESS SAFETY OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES IN HER2 POSITIVE BREAST CANCER (P&S Industry Clinical Trial)

    Feb 4 2015 - Feb 4 2020

    PHASE II TRIAL OF VELCADE? (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

    Dec 11 2014 - Dec 11 2019

    COLUMBIA UNIVERSITY MINORITY/UNDERSERVED SITE NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM (Federal Gov)

    Aug 1 2014 - Jul 31 2019

    A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE FAILED WHOLE BRAIN RADIATION THERAPY (P&S Industry Clinical Trial)

    Jul 18 2014 - Jul 18 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    A PHASE II, TWO TIER STUDY EVALUATING THE EFFICACY AND SAFETY OF SELINEXOR (KPT 330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA AFTER FAILURE OF RADIATION THERAPY AND TEMOZOLOMIDE (P&S Industry Clinical Trial)

    Jun 20 2014 - Jun 20 2019

    A PHASE IB/II, OPEN LABEL, MULITCENTER STUDY OF INC280 IN COMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

    May 14 2014 - May 14 2019

    A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL LDE225 VERSUS TEMOZOLOMIDE IN PATIENTS WITH HH-PATHWAY ACTIVATED RELAPSED MEDULLOBLASTOMA (P&S Industry Clinical Trial)

    Oct 2 2013 - Oct 2 2018

    A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ABT-414 IN COMBINATION WITH RADIATION PLUS TEMOZOLOMIDE OR TEMOZOLOMIDE ALONE (P&S Industry Clinical Trial)

    Aug 13 2013 - Aug 13 2018

    AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PLX3397 IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (P&S Industry Clinical Trial)

    Jul 26 2013 - Jul 26 2018

    IDENTIFYING LEPTOMENINGEAL METASTASIS FROM BREAST CANCER UTILIZING A NOVEL IMMUNOCYTOCHEMICAL MICROFLUIDIC DEVICE (Federal Gov)

    Jul 15 2016 - Jun 30 2018

    PHASE II STUDY OF AMG 386 WITH AND WITHOUT BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA (P&S Industry Clinical Trial)

    Apr 23 2013 - Apr 23 2018

    PILOT STUDY OF EGFR INHIBITION USING HIGH DOSE ADMINISTRATION OF ERLOTINIB WEEKLY FOR RECURRENT MALIGNANT GLIOMAS WITH EGFR VARIANT III MUTATION - PILOT STUDY OF EGFR INHIBITION FOR GMB (P&S Industry Clinical Trial)

    Jan 10 2013 - Jan 10 2018

    CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION (INTELLANCE 1) (RTOG 3508) (Private)

    Sep 1 2015 - Aug 31 2016

    A PHASE 2 STUDY OF MEDI-575 IN ADULT SUBJECTS WITH RECURRENTGLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

    Jan 5 2011 - Jan 5 2016

    PHASE II CLINICAL TRIAL OF PERIFOSINE + TEMSIROLIMUS FOR RECURRENT GLIOBLASTOMA WITH TISSUE AND IMAGING CORRELATES OF RESPONSE (Private)

    Jan 1 2013 - Dec 31 2015

    COLUMBIA UNIVERSITY MEDICAL CENTER MINORITY-BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM (MB-CCOP) (Federal Gov)

    Aug 6 2012 - May 31 2015

    RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)

    Jan 1 2009 - Dec 31 2014

    PULSATILE KINASE INHIBITOR THERAPY FOR MALIGNANT GILOMA: PROOF OF CONCEPT CLINICAL TRIAL (Private)

    Jun 1 2013 - May 31 2014

Clinical Trials

Multiple clinical trials for patients with brain tumors metastases